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Introduction
• Non diabetic endocrine emergencies rare
• Consider clinical situations that require immediate 
attention and the need for specialist referral
• Mix of clinical scenarios and what we see in 
paediatrics
Case study 1
• 3/52 baby
o 2nd opinion
o ? Future management
• Born at term
• Weight 4.53kg
• Non-consanguineous parents
• No family history
Case study 1
• Ante-natal USS
o Boy
• Baby born
o Male SOR assigned
o Given a male name
• Post natal check
o No testes in scrotum
• Urgent USS..
• DIAGNOSIS?
• Normal bladder and 
kidneys
• No testes or ovaries
• Chromosomes
o 46XX
• Bloods
o ↑ 17OHP
• 101.9nmol/L (NR: 0-
5nmol/L) 
• Local Paediatrician
o 21OHD CAH
o Hydrocortisone and 
Fludrocortisone
Referral to tertiary centre
• Parents very anxious
o Genital reconstructive surgery
• Referral into the DSD MDT
• On examination
o Prader V in Prader scoring system
46XX CAH
o Baby will have been exposed to 
excess male hormone in-utero
o The genitalia will look like a boy’s:
• Labia will fuse to look like a 
scrotum
• Clitoris enlarges and looks like 
a penis
o Can sometimes be so severe, sex 
assignment is difficult
• Need karyotype
• Will still have normal internal 
structures
• Surgery may be needed to 
correct outer appearance
o CONTROVERSIAL
• Exposure to prenatal 
androgens and Prader 3 
virilisation at birth
• Same baby at age 8 weeks at 
the time of genital 
reconstruction, showing some 
regression of virilisation after 
starting steroid treatment
• Another baby girl with a more 
severe form of 21OHD,
leading to more
severe virilisation 
(Prader IV)
Further investigations
• Repeat Pelvic USS
o No testes
o Ovaries seen
• Review of management, including intensive 
support and input from CNS
Change from hydrocortisone 
suspension to tablets
Medication review
• Stay on same dose of Fludrocortisone
• Hydrocortisone suspension tds
o 2/2/3mg
• Changed to hydrocortisone 10mg tablets 
• 1.25mg qds
• Guidance given on crushing and mixing with water  breast milk
• Dosage titrated against BSA calculations
o Side effects of underdosing → androgenisation
o Side effects of overdosing → Cushings
o Regular bloods
• Intensive emergency management training
o x 3 emergency hydcrocortisone packs prescribed and administered

What is a DSD?
• Congenital conditions in which 
development of chromosomal, gonadal or 
anatomic sex is atypical
• True genital ambiguity
o 1 in 5000 / 1 in 4500 births
• Genital anomalies
o 1 in 300 births
Classification of DSD
• Sex chromosome DSD (variable)
o Turner syndrome
o Klinefelter syndrome
o Mixed gonadal dysgenesis
• 46,XY DSD (under virilised genetic 
male)
o Disorders of testicular development
• Ovotesticular DSD
o Disorders of androgen synthesis / 
action
• CAIS
o Others
• Hypospadias
• 46,XX DSD (over virilised genetic 
female)
o Disorders of ovarian development
• Ovotesticular DSD
o Androgen excess
• CAH
Case study 2
January 2001 February 2002
Case study 2
• Facial appearance
o ‘Moon face’
• Weight gain
o Truncal obesity
o Buffalo hump
• Skin
o Thin and fragile
o Stretch marks
• Muscle weakness
• Mood disturbance
• Menstrual disturbance
• Hypertension
• Related excess androgen 
production
• Growth failure in children
• Abnormal virilisation
Abnormal virilisation in a 6.2 yr old 
prepubertal boy with Cushing’s disease 

Rapid progression of severe paediatric 
Cushing’s disease in an 6.2 yr old boy
Age 4 yrs Age 5 yrs
Age 6 years
• 2 year history of rapid 
weight gain
• Purple striae
• Depressive state
• Growth failure
• Hypertension 135/55
• Virilised
o G3 P2 Prepubertal testes
• Raised liver enzymes
• Abdominal U/S
o Enlarged fat laden liver
o Enlarged adrenals
Endocrine investigations?
• Urinary free cortisol
o 1098nmol/24h (NR 40 – 340)
• Midnight cortisol
o >1650nmol/l (NR <50)
• Low dose dexamethasone suppression test
o Failure to suppress cortisol (>1650nmol/l)
• Adrenal androgens
o Raised:
• Androstenedione 36.3 nmol/l (NR <1.0)
• DHEA-S 1.4 𝛍𝐦𝐨𝐥/𝐥 (NR <0.5)
• Testosterone 8.1 nmol/l (NR <0.8)
Next steps?
Pituitary surgery?
Adrenalectomy?
Pituitary surgery plan
• Control the hypercortisolaemia
• Stabilise the child’s general condition
• Treatment was initiated with ketoconazole 200 mg 
8-hourly, but discontinued after 6 weeks due to 
deteriorating liver function
• Metyrapone 250 mg 8-hourly was substituted but 
was not tolerated even when given by naso-gastric 
tube, because of persistent nausea and vomiting
The serum cortisol remained elevated at
> 1,250 nmol/l
What happened next?
• The child’s general condition deteriorated rapidly 
with hyponatraemia secondary to persistent 
vomiting, inadequate nutritional support and 
incipient respiratory failure
• The decision was taken to transfer the child to a
PICU and to stabilise his condition in preparation
for bilateral adrenalectomy
o Life saving procedure!
How could his 
hypercortisolaemia be 
controlled prior to 
surgery?
Severe Cushings - Etomidate
• Etomidate
o IV anaesthetic 
agent
o Suppresses 
corticosteroid 
synthesis
• Adrenal 
suppression
Control of hypercortisolaemia with 
adrenolytic therapy - IV Etomidate
Finally.. Progress!
• Post-operatively, the 
patient made good 
progress
• Serum cortisol pre-
hydrocortisone was 
<20 nmol/l, indicating 
removal of all adrenal 
tissue, and he 
recovered steadily on 
replacement therapy 
of hydrocortisone 5 mg 
three times daily and 
fludrocortisone 50g 
twice daily
Case study 3 – 13 week 
old baby girl
• On examination
o Pale
o Still
o Weight 5.36 kg (-1.05 SD)
o Length 60.5cm (0.21 SD)
o Hypotonic
o Roving nystagmus
• Likely diagnosis?
• What further 
assessment is needed?
• Admitted for poor 
feeding
o Born at 41 weeks
o Weighed 3.4kg
o Mother was 29 years of age
o Hypoglycaemic at 24 hours
o Phototherapy for jaundice
o 6 weeks
• Not fixing and following 
o 10 weeks
• Small optic discs
• Absent electroretinogram
response to light
Septo Optic Dysplasia
Corpus
callosum
Septum 
pellucidum
Optic nerves 
Pituitary
Why?
• Cranial ultrasound
• MRI
o Absence of septum pellucidum
• Bloods
o T4
o TSH
o Random cortisol
o Electrolytes
• Nystagmus
• Failure to fix and follow
• Neonatal 
hypoglycaemia
• Jaundice
o Optic Nerve Hypoplasia
o Hypopituitarism
What would the results show?
• Free T4
o 13.9pmol/L (NR 10-20)
• TSH on stimulation test
o 0 mins 3.8
o 30 mins 26
o 60 mins 33 mU/L (NR 0.5 – 5)
• Peak GH on stimulation
o Low normal 8µg/L (NR >7)
• Serum sodium
o 163mmol/L (NR 135 - 145
• Urine osmolality
o 132mOsm/kg 
• NR 500 – 800 mOsm/kg water
o Large values = 
concentrated urine
o Lower values = dilute 
urine
• Random cortisol
o 220nmol/L (NR >500)
• Peak cortisol on standard 
synacthen test (ACTH 
250mcg)
o 1269nmol/L
TRH test
• TRH 7 mcg/kg slow IV injection over 3 mins
• Interpretation
o In normal people, a rise in TSH at 20 mins with a fall at 60 is seen
o In hypothalamic hypothyroidism
• TSH increases at 20m, and 
continues to rise at 60
o In hypothyroidism 2° to 
hypopituitarism
• No change in TSH level  
What do the results 
mean?
What treatment should 
the baby have?
Further diagnosis and 
treatment
• DDAVP
o 25mcg daily initially
• Thyroxine
o FT4 falls to 8.9pmol/L at age 5 
months
What happens next with 
the baby?
• Baby has diabetes 
insipidus
• Hypothalamic 
hypothyroidism
• No cortisol deficiency
WHY?
Baby unwell again
• Admitted acutely unwell to the ER
o Poor perfusion
o Mottled and cold peripheries
o Capillary glucose 1.3mmol/L (NR 4-7)
o Sodium
• 167mmol/L
o Lab glucose
• 2.2mol/L
o Treatment?
• IV fluids
• DDAVP dose adjusted
• DI difficult to control
o Sodium fluctuating between130 and 156 mmol/L
What is the explanation for the poor progress?
ACTH deficient
• Random cortisols
during illness were 
never >500
• Baby started on 
hydrocortisone
o When on full replacement 
• DI stabilised
• Height
o Remained on 10th centile
o Age 5 years 
• Fell to 3rd centile
• GH therapy commenced
• DI cannot be properly 
controlled with cortisol 
deficiency
o Latter required for water 
excretion
• Peak cortisol on 
synacthen was 
exaggerated as low 
dose was not used
• IM injection after time 0
o < 6/12 : 62.5mcg
o 6/12 – 2yrs : 125mcg
o > 2yrs: 250 mcg
Comments on Case Study 3
• Difficulty in diagnosing adrenal insufficiency
• Important role of cortisol in water balance
• Evolving pattern of GHD in SOD
o Normal levels often found in infancy
Case study 4
• Baby aged 10 days referred to the paediatric
endocrine clinic
• Fit and well
o Beginning to feed poorly
o Slightly jaundiced
What could be the indication for referral?
Congenital hypothyroidism
Congenital 
hypothyroidism
• All babies screened at 
5 days of life
o Guthrie Test - TSH
• Sleepiness
• Poor feeding
• Constipation
• Goitre
• Oedema
• Jaundice
• Treatment:
o Thyroxine tablets
• 100 mcg / m2 / day
Screening
• Guthrie card at 5-8 days – detects TSH
• Notification if positive TSH >20mU/L
• Start treatment within 24 hours
• If borderline TSH 6-19.9mU/L - repeat
• Thyroid isotope scan usually 
performed
o Assess size and site of gland
Technetium scan
Flow sheet false positive
Date TSH Free T4 Free 
T3
Thyroxin
e dose 
(mcg)
Comments
13/8/2015 7.43 (<6) 20.7 (12.5-
24.6)
- Rpt 2/52
27/8/2015 5.2 19.2 - Discharge
Blood spot 26mU/l
Flow sheet double 
borderline
Date TSH Free T4 Thyroxine
dose (mcg)
Comments
30/5/2015 26.2 (<6) 15.3 (12.5-24.6) - Started 25mcg OD
12/6/2015 6.1 18.7 (9-19.6) 25 mcg 
OD
Continue 
31/7/2015 19.2 14.0 25 mcg 
OD
Increase to 35mcg OD
1/10/2015 0.6 23.6 35mcg OD Reduced to 30mcg 
OD
2/2/2016 3.4 15.3 30mcg OD Continue
1/4/2016 1.2 19.2 30mcg OD Continue
2/6/2016 2.2 16.7 30mcg OD Switched to tablets
37.5/25 mcg OD
1st blood spot 9.8mU/l; 2nd spot 10mU/l
Congenital 
hypothyroidism
• Thyroid 
dysgenesis
oMissing
o Ectopic
o Underdeveloped
• Defects in T4 synthesis 
• TRH and TSH deficiency
• TSH receptor defect
• Maternal disease 
o Drugs
• Trisomy 21
Thyroid gland 
development – 4- 7 weeks
• Thyroglossal duct 
degenerates between 7-
10 weeks
• Thyroid reaches its end 
location anterior to the 
trachea by week 7
• If parts of the duct remain 
the person may also have 
a pyramidal lobe
o 50% of the population
• Ectopic thyroid tissue left 
behind during migration
o Common but asymptomatic
o Parts of the duct may persist
• Midline, movable cyst in the 
child
Treatment and follow up
Follow up
• Development, 
hearing and growth
• Often subtle speech 
delay
• Detect those with 
transient neonatal 
hypothyroidism
• Decision on 
withdrawal at 3 
years
Treatment
• Thyroxine
o 25-50 mcg daily 
(10mcg/kg/d)
o Crushed tablet or 
solution
o NOT suspension
• Limited stability
• Neonates have higher 
normal range fT4
• Maintain in upper half 
of normal range
Case study 5
• Presentation of newborn baby
o Tachycardic
o Irritability
o Restlessness
o Hypertensive
o Exophthalmos
o Periorbital oedema
o Goitre
Neonatal thyrotoxicosis
• Usually simply 
biochemical
• Signs and symptoms
o Goitre
o Tachycardia
o Arrthymias
o Hypertension
o Cardiac failure
o ↑ appetite
o Weight loss
o Diarrhoea
o Irritability
o Exophthalmus
• Caused by trans-
placental transfer of 
maternal TSH receptor 
antibodies
o Stimulates the foetal and 
neonatal thyroid gland
• May occur in infants 
with mothers of some 
degree of 
hyperthyroidism

Case study 7
• On examination
o Overweight
o BMI – 98 / 99%ile
o Pink stretch marks
o Acanthosis nigricans
o Blood glucose
• 26mmol/L (468mg/dL)
• Not acidotic
o Urine
• 3+ glucose
• Moderate ketones
• Diagnosis?
• Investigations?
• Treatment?
• 14 year old Asian girl 
o 6 week history 
• Polyuria
• Polydipsia
• Weight loss
• Grandfather 
developed diabetes in 
his 50s and takes 
tablets
Type 2 diabetes
• High risk ethnic group
• Family history
• Acanthosis
• BMI – obese
• Ketonuria
o Unusual, but does occur in a 3rd of cases
• Because of the weight loss and ketonuria
o Difficult to diagnose between Type 1 and Type 2 diabetes
Investigations to confirm?
• Islet cell and GAD antibodies
o GAD test
• Blood test to measure whether the body is producing a type of 
antibody which destroys its own GAD cells
o Negative in Type 2
o Positive in Type 1
• C-Peptide
o Reflects amount of natural insulin that the child is producing 
• Normal or increased in Type 2
• Low in Type 1
Treatment
• Results of bloods may take some weeks…
o High blood glucose
o Ketosis
• Basal bolus regime of insulin
• Dietary treatment and good exercise 
regime very important
o When ketosis has resolved
o Blood glucose lowered
• Metformin gradually introduced
o Gradually increase
o Decrease then stop insulin
National Child Measurement 
Programme
• Measures and records the height and weight of 
over one million children each year in the UK
o Reception age (4-5 years)
o End of primary school age (10-11 years)
• Principally to assess weight and obesity levels in 
schools
• Parents can opt out
Prevalence of excess weight among 
children in the UK – 2014 / 2015
53
One in five children in Reception is overweight or obese (boys 22.6%, girls 21.2%)
One in three children in Year 6 is overweight or obese (boys 34.9%, girls 31.5%)
Obesity prevalence by ethnic group: Year 6
NCMP 2014/15
54
Child obesity: BMI ≥ 95th centile of the UK90 growth reference
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Causes of increasing 
childhood obesity
• Genes
o Monogenic
o Polygenic
o Co-morbidity genes
• Environment
o Quality of food supply
o Food convenience
o Food industry
o Price
o Activity
Food industry
• £600 million spent last year marketing high sugar 
products to children
• Advertising – traditional and new
• Advergames
o Promoting material to websites
• Characters
• Social media
• Sponsorship of events, programmes                                                    
and infrastructure
Management of Type 2 
Diabetes
• Education
• Behavioural changes
• Dietary management
• Glycaemic monitoring 
• Pharmacological 
therapy
o Decrease insulin resistance
o Increase insulin secretion
o Slow post prandial glucose 
absorption
• Biguanides
o Metformin
o Acts on insulin receptors in liver, 
muscle and fat tissue
o Long term use – associated 
with 1 – 2% reduction in HbA1c
• Insulin
o Small doses can be effective
• Sulphonylureas
o Increase insulin secretion
• Useful when there is 
residual beta cell function
Paediatric Emergencies
• Some more urgent 
than others
o Urgent treatment
o Urgent referral
Differences between 
adults and 
paediatrics?
DSD
Cushing's
SOD
CH
Neonatal 
thyroitoxicosis
Diabetes
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